Yasunori Kaneko
Fortune : 24 M $ au 31/05/2026
Fortune : 24 M $ au 31/05/2026
Yasunori Kaneko is currently Lead Independent Director at Arcus Biosciences, Inc. since 2015 and Director at Provigate KK.
Former roles include Director at LeukoSite, Inc., KAI Pharmaceuticals, Inc., Guava Technologies, Inc., and Independent Director at H.U.
Group Holdings, Inc. Served as Independent Outside Director at Nippon Paint Holdings Co., Ltd. from 2018 to 2020.
Managing Director at Skyline Management LLC and Skyline Venture Partners LP from 1999 to 2019.
Chief Financial Officer & Senior Vice President at Ionis Pharmaceuticals, Inc. from 1991 to 1992.
Chief Financial Officer & VP-Business Development at Tularik, Inc. from 1992 to 1998.
Head-Corporate Finance at Paribas Capital Markets from 1987 to 1991.
Education includes undergraduate and doctorate degrees from Keio University and an MBA from Stanford Graduate School of Business.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC. 0,76 % | 11/06/2026 | 957 955 ( 0,76 % ) | 24 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/05/2015 |
Provigate KK
Provigate KK Medical SpecialtiesHealth Technology Manufactures and sells tear sugar measurement devices | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| NIPPON PAINT HOLDINGS CO., LTD. | Directeur/Membre du Conseil | 01/03/2020 |
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare market, including biotechnology, therapeutics, medical devices, consumables and equipment for life sciences research and healthcare information technology. It participates in financing for early stage and later stage transactions with an investment size between USD 15 and 25 million. | Private Equity Investor | 01/01/2019 |
Skyline Venture Partners LP
Skyline Venture Partners LP Investment ManagersFinance Acts as Venture Capital Fund | Corporate Officer/Principal | 01/01/2019 |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Directeur/Membre du Conseil | 01/01/1999 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in cancer and inflammatory disease treatments | Directeur Financier/CFO | 01/01/1998 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 14 |
|---|---|
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in cancer and inflammatory disease treatments | Commercial Services |
KAI Pharmaceuticals, Inc.
KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical drugs | Health Technology |
Nippon Paint Holdings Co., Ltd.
Nippon Paint Holdings Co., Ltd. Industrial SpecialtiesProcess Industries Manufactures and distributes paints and fine chemicals | Process Industries |
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare market, including biotechnology, therapeutics, medical devices, consumables and equipment for life sciences research and healthcare information technology. It participates in financing for early stage and later stage transactions with an investment size between USD 15 and 25 million. | Finance |
Keio University
Keio University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Guava Technologies, Inc.
Guava Technologies, Inc. BiotechnologyHealth Technology Develops, manufactures and commercializes cytometry systems for cellular analyses | Health Technology |
H.U. Group Holdings, Inc.
H.U. Group Holdings, Inc. Medical/Nursing ServicesHealth Services Operates as a holding company with interests in manufacturing of diagnostic drugs and equipments | Health Services |
Skyline Venture Partners LP
Skyline Venture Partners LP Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Paribas Capital Markets
Paribas Capital Markets Investment Banks/BrokersFinance Provides brokerage services | Finance |
Stanford Graduate School of Business
Stanford Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. BiotechnologyHealth Technology Develops and commercializes novel therapies for the treatment of lung & gastrointestinal cancers | Health Technology |
Provigate KK
Provigate KK Medical SpecialtiesHealth Technology Manufactures and sells tear sugar measurement devices | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national